CDK4/6 inhibitorFDA-approvedSecond-line
Ribociclib
How it works
Blocks the CDK4/6 enzymes that drive cell division in cancer cells, causing them to die.
Cancer types
Breast Cancer— Hormone receptor-positive
Efficacy
Ribociclib has been shown to improve progression-free survival in patients with hormone receptor-positive, HER2-negative metastatic breast cancer, particularly when combined with letrozole.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Camizestrant and Ribociclib in Advanced Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Ribociclib and Palbociclib Show Similar Efficacy in Treating Metastatic Breast Cancer | Breast Cancer | observational | The 24-month PFS rates were comparable between the ribociclib and palbociclib cohorts (55.4% vs. 55.2%, respectively). | Source → |
| Continued Access to Ribociclib for Metastatic Breast Cancer | Breast Cancer | preclinical | — | Source → |
| Testing Hormone Therapy with Ribociclib for Breast Cancer Treatment | Breast Cancer | phase-3 | — | Source → |
| Evaluating CDK4/6 Inhibitors for Metastatic Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Evaluating Camizestrant and Ribociclib for Hormone-Receptor Positive Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Older cancer patients may need special monitoring for certain medications | Breast Cancer | observational | — | Source → |
| Study of Omitting Chemo in ER-Positive, HER2-Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Studying Ribociclib and Chemotherapy for High-Risk Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing a Combination Treatment for HER2 Positive Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Comparing a New Therapy to Chemotherapy for Early Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Evaluating Leucogen to Prevent Low White Blood Cell Count in Breast Cancer Patients Taking Ribociclib | Breast Cancer | phase-2 | — | Source → |
| Evaluating a New Treatment Combination for Advanced Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Ribociclib and Hormone Therapy in Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Assessing the Effectiveness and Safety of Ribociclib in Breast Cancer Treatment | Breast Cancer | preclinical | — | Source → |
| Evaluating Patient Outcomes with Ribociclib in Early-Stage Breast Cancer | Breast Cancer | preclinical | — | Source → |
| Study of Ribociclib and Hormone Therapy in Early Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Testing Letrozole and Ribociclib in Early Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Ribociclib and Letrozole Effective in Older Women with Advanced Breast Cancer | Breast Cancer | preclinical | The median progression-free survival was 36 months, and the breast cancer-specific survival rate at 24 and 36 months was 82% and 75%, respectively. | Source → |
| Cyclin Dependent Kinase Inhibitors in Metastatic Breast Cancer | Breast Cancer | observational | In patients receiving palbociclib, a better median progression-free survival (PFS) was observed in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 1 (27.3 months,p-value <0.0001), de novo disease (17.5 months,p-value 0.0155), first line hormonal therapy (22.5 months,p-value <0.0001) and no prior chemotherapy (20.3 months,p-value 0.0001). | Source → |
| Combining Ferulic Acid with Breast Cancer Drugs May Improve Treatment | Breast Cancer | lab-study | — | Source → |
| New Nanoparticle Delivery System for Breast Cancer Treatment | Breast Cancer | lab-study | The RIB-LNC exhibited a 1.31-fold and 3.09-fold reduction in IC values in MDA-MB-231 and MCF-7 cells, respectively, as compared to free RIB. | Source → |
| New Treatment Combination Approved for High-Risk Breast Cancer | Breast Cancer | phase-3 | The invasive disease-free survival at 36 months was 90.7% for Ribo + AI versus 87.6% for AI, with a hazard ratio of 0.75. | Source → |
| CDK4/6 Inhibitors Linked to Cardiotoxic Events in Breast Cancer Patients | Breast Cancer | observational | — | Source → |
| Ribociclib Improves Survival in Early Breast Cancer | Breast Cancer | phase-3 | At 3 years, invasive disease-free survival was 90.4% with ribociclib plus an NSAI and 87.1% with an NSAI alone. | Source → |
| CDK4/6 Inhibitors and Endocrine Therapy for Metastatic Breast Cancer | Breast Cancer | phase-3 | Ribociclib combined with letrozole significantly improved PFS over letrozole alone. | Source → |
| Targeted Liposomes Deliver Cancer Drug to Breast Cancer Cells | Breast Cancer | lab-study | — | Source → |
| Combining Cancer Drugs May Help or Hinder Treatment in Colorectal Cancer | Colorectal Cancer | lab-study | — | Source → |
| Combining chemotherapy and ribociclib in ovarian cancer treatment | Ovarian Cancer | phase-1 | The overall response rate was 79.3%, with a clinical benefit rate of 96.6%. | Source → |
| Ribociclib Improves Survival in Advanced Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Ribociclib plus Endocrine Therapy May Improve Survival in Some Breast Cancer Patients | Breast Cancer | phase-3 | Median overall survival was 58.7 months with ribociclib versus 48.0 months with placebo. | Source → |
| Tumor Subtype Affects Outcomes in Breast Cancer Patients | Breast Cancer | phase-3 | — | Source → |
| Comparing Two Cancer Treatments in Younger Women | Breast Cancer | observational | The median progression-free survival was 24.05 months for palbociclib and 24.41 months for ribociclib. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.